PMID- 19419595
OWN - NLM
STAT- MEDLINE
DCOM- 20091123
LR  - 20161020
IS  - 1469-5111 (Electronic)
IS  - 1461-1457 (Linking)
VI  - 12
IP  - 9
DP  - 2009 Oct
TI  - Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. 
      haloperidol.
PG  - 1233-48
LID - 10.1017/S1461145709000352 [doi]
AB  - To compare the remission rate and its time-course over 196 wk of double-blind 
      treatment with an atypical antipsychotic, ziprasidone (80-160 mg/d given b.i.d., 
      or 80-120 mg/d given q.d.), or a conventional antipsychotic, haloperidol (5-20 
      mg/d). Outcome assessments included attainment of remission (Andreasen criteria) 
      by longitudinal analysis. Positive and Negative Syndrome Scale (PANSS) scores, 
      Global Assessment of Functioning Scale (GAF) scores, and quality-of-life (QLS) 
      were also assessed in the initial 40-wk study phase (n=599) and the 3-yr 
      extension study (n=186). Discontinuation rates in the initial 40-wk core and 
      follow-up extension studies were comparable between groups: 64% and 65% for the 
      80-160 mg/d ziprasidone group, 65% and 58% for the 80-120 mg/d ziprasidone group, 
      and 60% and 66% for the 5-20 mg/d haloperidol group, respectively. Mean change 
      scores from baseline to LOCF endpoint (week 40 or early termination) for PANSS 
      negative and GAF (primary efficacy variables) were not statistically 
      significantly different between ziprasidone and haloperidol. During the 3-yr 
      extension study, ziprasidone-treated subjects (80-160 mg/d) were more likely to 
      achieve remission (51%) than haloperidol-treated (40%) subjects (p=0.04), while 
      there was a favourable trend associated with 80-120 mg/d ziprasidone (48%). 
      Compared to the haloperidol group, subjects assigned to the 80-160 mg/d 
      ziprasidone group showed a gradual and persistent improvement in remission 
      (p=0.006) and quality-of-life (p=0.004) in the longitudinal analyses. Significant 
      differences in the trajectory of PANSS total and GAF scores favouring the 80-160 
      mg/d ziprasidone group were also observed. In this long-term, double-blind study, 
      ziprasidone treatment was more likely to result in remission than haloperidol 
      treatment, and was associated with greater improvement in quality-of-life.
FAU - Potkin, Steven G
AU  - Potkin SG
AD  - Department of Psychiatry and Human Behavior, University of California, Irvine, 
      CA, USA. sgpotkin@uci.edu
FAU - Weiden, Peter J
AU  - Weiden PJ
FAU - Loebel, Antony D
AU  - Loebel AD
FAU - Warrington, Lewis E
AU  - Warrington LE
FAU - Watsky, Eric J
AU  - Watsky EJ
FAU - Siu, Cynthia O
AU  - Siu CO
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090507
PL  - England
TA  - Int J Neuropsychopharmacol
JT  - The international journal of neuropsychopharmacology
JID - 9815893
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Piperazines)
RN  - 0 (Thiazoles)
RN  - 6UKA5VEJ6X (ziprasidone)
RN  - J6292F8L3D (Haloperidol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Haloperidol/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Dropouts
MH  - Piperazines/adverse effects/*therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Quality of Life
MH  - Remission Induction
MH  - Schizophrenia/*drug therapy
MH  - *Schizophrenic Psychology
MH  - Thiazoles/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2009/05/08 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/05/08 09:00
PHST- 2009/05/08 09:00 [entrez]
PHST- 2009/05/08 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S1461145709000352 [pii]
AID - 10.1017/S1461145709000352 [doi]
PST - ppublish
SO  - Int J Neuropsychopharmacol. 2009 Oct;12(9):1233-48. doi: 
      10.1017/S1461145709000352. Epub 2009 May 7.